Milestone Pharmaceuticals secures $105 mln in RTW-led round
Montréal-based cardiovascular drug developer Milestone Pharmaceuticals has raised $80 million in its latest financing. U.S. life sciences investment firm RTW Investments led the round. It was joined by other new investors, including Venrock Healthcare Capital Partners and Tavistock Group, and existing investors, including Novo Holdings A/S, Forbion Capital Partners, Tekla Capital Management, Domain Associates, BDC Capital, Pappas Capital, GO Capital and Fonds de solidarité FTQ. Milestone will use the funds raised for its Phase 3 clinical program, pre-launch activities of etripamil, a new drug for treating paroxysmal supraventricular tachycardia, and expanding its pipeline. Led by President and CEO Joseph Oliveto, Milestone closed a $68 million Series C round last year.
